Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pediatric COVID-19 Vaccine Face-Off Looms As Bharat Biotech Heads For Approval

Supply, Acceptance Key

Executive Summary

While Bharat Biotech is close to an accelerated approval of Covaxin in two to 18-year-olds, Zydus Cadila is yet to roll out its COVID-19 vaccine in India. As they head to a face-off in pediatric vaccines, the former faces manufacturing constraints and the latter hesitance over a first of its kind DNA vaccine. Experts speak to Scrip on which one stands a better chance of winning.

You may also be interested in...



Zydus Cadila Turns DNA Pioneer With COVID-19 Vaccine Approval

With an emergency approval, Zydus Cadila has commercialized the world’s first plasmid DNA vaccine for human use and the first COVID-19 vaccine for use in adolescents in India. Will efficacy against the Delta variant help tide over hesitancy towards a new technology or a lack of publicly published data hamper acceptance?

Can Delta Variant Effectiveness Fill Brazil-Sized Hole In Bharat Biotech’s Prospects?

A study indicates that the Delta variant of SARS-CoV-2 and its sub-lineage Delta Plus can be neutralized by Bharat Biotech’s COVID-19 vaccine, but a federal investigation in Brazil and a class action suit against its US partner have hurt the firm’s global ambitions. Experts weigh in on what the future could possibly hold.

Global Herd Immunity Against COVID-19 Unlikely, Says Ebola Vaccine Developer

As coronavirus variants keep emerging, global herd immunity is unlikely, says Steven Jones, one of the developers of the first Ebola vaccine. In a wide-ranging discussion with McKinsey, he and other experts weighed in on ways to live with COVID-19, which is expected to soon become endemic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel